跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
Hsin Wei Liao
, Jung Mao Hsu
, Weiya Xia
, Hung Ling Wang
, Ying Nai Wang
, Wei Chao Chang
, Stefan T. Arold
, Chao Kai Chou
, Pei Hsiang Tsou
, Hirohito Yamaguchi
, Yueh Fu Fang
, Hong Jen Lee
, Heng Huan Lee
,
Shyh Kuan Tai
,
Mhu Hwa Yang
, Maria P. Morelli
, Malabika Sen
, John E. Ladbury
, Chung Hsuan Chen
, Jennifer R. Grandis
Scott Kopetz, Mien Chie Hung
*
顯示 2 更多
顯示較少
*
此作品的通信作者
醫學系耳鼻喉學科
國立陽明交通大學
臨床醫學研究所
研究成果
:
Article
›
同行評審
134
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Anti-EGFR Antibody
20%
Cancer Xenograft Model
20%
Cell Proliferation
20%
Cetuximab
100%
Colorectal Cancer Patients
20%
EGF Receptor
100%
EGFR Extracellular Domain
20%
Extracellular Domain
20%
High Recurrence Rate
20%
Intracellular Domain
20%
Methylation
100%
Methylation Status
20%
Model Expression
20%
Orthotopic Colorectal Cancer
20%
Overall Survival
20%
Post-translational Modification
20%
PRMT1
100%
Receptor Dimerization
20%
Receptor Signaling
20%
Signal Activation
40%
Sustained Signaling
20%
Tumor Growth
20%
Biochemistry, Genetics and Molecular Biology
Arginine
100%
Cell Proliferation
10%
Cetuximab
100%
Dimerization
10%
Epidermal Growth Factor Receptor
100%
Methylation
100%
Methyltransferase
100%
Monoclonal Antibody
10%
Overall Survival
10%
Posttranslational Modification
10%
Tumor Progression
10%
Neuroscience
Cell Proliferation
10%
Cetuximab
100%
Colorectal Carcinoma
20%
Epidermal Growth Factor Receptor
100%
Methylation
100%
Monoclonal Antibody
10%
Posttranslational Modification
10%
Protein Arginine Methyltransferase
100%
Receptor
10%
Immunology and Microbiology
Arginine
100%
Cell Proliferation
16%
Cetuximab
100%
Colorectal Carcinoma
33%
Dimerization
16%
Methylation
100%
Monoclonal Antibody
16%
Overall Survival
16%
Protein Processing
16%
Xenograft
16%